Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Analysts at Citigroup

Citigroup started coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a neutral rating and a $895.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on REGN. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $756.81 on Thursday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $753.69 and a 12 month high of $1,211.20. The company has a 50 day simple moving average of $985.21 and a two-hundred day simple moving average of $1,033.97. The stock has a market cap of $83.17 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of REGN. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $26,000. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Finally, Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at about $28,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.